Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Nov 2011 - :1791-2423 [PMID:22102168] [Fournier P] [Arnold A] [Wilden H] [Schirrmacher V]
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Okt 2011 - :1791-2423 [PMID:21971670] [Fournier P] [Wilden H] [Schirrmacher V]
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Sep 2011 - Methods Mol. Biol.; 797:1940-6029 [PMID:21948477] [Fournier P] [Bian H] [Szeberényi J] [Schirrmacher V]
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity. Apr 2011 - Int. J. Oncol.; 38(6):1791-2423 [PMID:21424118] [Fournier P] [Aigner M] [Schirrmacher V]
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity. Jan 2011 - :1873-2518 [PMID:21172381] [Ni J] [Galani IE] [Cerwenka A] [Schirrmacher V] [Fournier P]
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. Nov 2010 - Int. J. Oncol.; 37(6):1791-2423 [PMID:21042712] [Fournier P] [Aigner M] [Schirrmacher V]
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Sep 2010 - Int. J. Oncol.; 37(5):1791-2423 [PMID:20878068] [Fournier P] [Aigner M] [Schirrmacher V]
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination. Aug 2010 - :1873-2518 [PMID:20709006] [Ni J] [Schirrmacher V] [Fournier P]
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. Jul 2009 - J. Virol.; 83(16):1098-5514 [PMID:19515783] [Jarahian M] [Watzl C] [Fournier P] [Arnold A] [Djandji D] [Zahedi S] [Cerwenka A] [Paschen A] [Schirrmacher V] [Momburg F]
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Jul 2009 - Methods Mol. Biol.; 542:1064-3745 [PMID:19565923] [Schirrmacher V] [Fournier P]
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Mrz 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287954] [Wilden H] [Fournier P] [Zawatzky R] [Schirrmacher V]
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797] [Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Jul 2008 - Virus Res.; 136(1-2):0168-1702 [PMID:18538434] [Zhao H] [Janke M] [Fournier P] [Schirrmacher V]
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Mrz 2008 - Int. J. Oncol.; 32(4):1019-6439 [PMID:18360705] [Aigner M] [Janke M] [Lulei M] [Beckhove P] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Nov 2007 - Gene Ther.; 14(23):0969-7128 [PMID:17914407] [Janke M] [Peeters B] [de Leeuw O] [Moorman R] [Arnold A] [Fournier P] [Schirrmacher V]
